iCARE HBsAg Rapid Test Kit

The iCARE HBsAg Rapid test kit has 99% sensitivity and specificity. To perform the test, you should immerse the test strip in serum or plasma. It is important to make sure that the strip does not pass the maximum line. The result should be read after 15 minutes. A weak line in the test region may indicate a low HBsAg concentration. If you do not see the line after 15 minutes, you should not interpret the test result.

99% sensitivity

The iCARE HBsAg Rapid test kit has 99% sensitivity, making it one of the most sensitive tests available. Its sensitivity is determined by the presence of HBsAg in the sample. It is also sensitive enough to identify reactivated HBsAg in serum samples. The test is easy to use and is recommended for routine testing.

The rapid test results of the iCARE HBsAg 2 kit are provided within 15 minutes. Its analytical sensitivity is 0.1 IU/mL, making it an excellent choice for rapid diagnosis. The test is based on an in vitro qualitative immunoassay method and detects HBsAg in whole blood and plasma. Its rapid results allow healthcare professionals to make an informed treatment decision. This rapid test kit is especially useful for underserved areas.

iCARE HBsAg Hepatitis B Surface Antigen Rapid Screen Test

99% specificity

To improve diagnosis, rapid test kits must be accurate compared to the gold standard. This study aimed to determine the sensitivity and specificity of three rapid HBsAg tests. The tests were tested on samples from various populations and settings. In addition, these tests were designed to minimize the number of false positive results and improve access to diagnosis in under-resourced areas.

The sensitivity and specificity of HBsAg kits are better than those of the HCV-Ab test. The sensitivity ranges from 73% to 100% and the NPV averages at 92%. Moreover, these PPV and NPV converge to 100% in the absence of an FN test result. However, the performance of these test kits varies from manufacturer to manufacturer. Therefore, they should be carefully evaluated before use in clinical practice.

About Author:

JAL Medical Singapore
Mr. Andre Han

Managing Director, JAL Medical Singapore

Mr. Andre Han is the Managing Director of JAL Medical Singapore, a strategic subsidiary of a publicly listed biomedical manufacturer headquartered in Hsinchu, Taiwan. The parent company is internationally recognized for its ISO 13485 and GMP-certified production capabilities, delivering high-quality diagnostic solutions to global healthcare markets.
With over 20 years of experience in the medical device industry, Mr. Han brings deep expertise in commercial strategy, product development, and international market expansion. He oversees a comprehensive portfolio that includes in-vitro diagnostic test kits and proprietary blood glucose monitoring systems tailored for both clinical and home environments. Under Mr. Han’s leadership, JAL Medical has:

  • Distributed hundreds of millions of rapid diagnostic test kits globally
  • Secured long-term national tenders in South Africa
  • Expanded into key markets including Laos, Mongolia, Ghana, Kenya, Ukraine, Nigeria, and Japan
Beyond commercial operations, Mr. Han spearheads consultancy initiatives focused on:
  • Rapid test innovation and development
  • Facility optimization and regulatory alignment
  • Enhancing quality, reliability, and affordability across product lines
His strategic vision and commitment to innovation continue to position JAL Medical Singapore as a trusted provider of accessible, high-performance healthcare technologies worldwide.

Listening Article